Education
About Us
Working with TipRanks
Follow Us
Bicara Therapeutics Inc. (BCAX)
NASDAQ:BCAX
BCAX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.10 - $28.09
Previous CloseN/A
Volume80.52K
Average Volume (3M)563.93K
Market Cap
$645.01M
Enterprise Value$459.37M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta>-0.01
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding54,523,327
10 Day Avg. Volume500,887
30 Day Avg. Volume563,931
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.64
Forecast
1Y Price Target
$40.00Price Target Upside201.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Bicara Therapeutics Inc. News
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressFicerafusp alfa addresses the key resistance mechanism associated with EGFR resistance.
Financial HealthBCAX ended 4Q with cash/equivalents of $489.7M, expected to fund operations into 1H29.
Market ValuationBCAX shares are significantly undervalued based on ficerafusp alfa’s broad potential in EGFR+ solid tumors and strong balance sheet that should support development until approval.
Bears Say
Enrollment ChallengesEnrollment in the Ph1/1b study is currently on hold due to possible changes in the standard of care in an earlier line of therapy.
Financial PerformanceThe company's GAAP net loss was wider than expected, driven by higher-than-expected operating expenses.
Safety Concerns46.4% of patients treated with the combo experienced a G3+ TRAE, with G3 ALT/AST elevations occurring in 14% and 7% of patients, respectively; 7.1% of patients discontinued treatment due to a TRAE.
---
Ownership Overview
37.38% Insiders
3.18% Mutual Funds
49.02% Other Institutional Investors
8.65% Public Companies and
Individual Investors
BCAX FAQ
What was Bicara Therapeutics Inc.’s price range in the past 12 months?
Bicara Therapeutics Inc. lowest stock price was $11.10 and its highest was $28.09 in the past 12 months.
What is Bicara Therapeutics Inc.’s market cap?
Bicara Therapeutics Inc.’s market cap is $645.01M.
When is Bicara Therapeutics Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Bicara Therapeutics Inc.’s earnings last quarter?
Bicara Therapeutics Inc. released its earnings results on Nov 12, 2024. The company reported -$1.6 earnings per share for the quarter, missing the consensus estimate of -$0.41 by -$1.19.
Is Bicara Therapeutics Inc. overvalued?
According to Wall Street analysts Bicara Therapeutics Inc.’s price is currently Undervalued.
Does Bicara Therapeutics Inc. pay dividends?
Bicara Therapeutics Inc. does not currently pay dividends.
What is Bicara Therapeutics Inc.’s EPS estimate?
Bicara Therapeutics Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bicara Therapeutics Inc. have?
Bicara Therapeutics Inc. has 54,523,327 shares outstanding.
What happened to Bicara Therapeutics Inc.’s price movement after its last earnings report?
Bicara Therapeutics Inc. reported an EPS of -$1.6 in its last earnings report, missing expectations of -$0.41. Following the earnings report the stock price went up 2.29%.
Which hedge fund is a major shareholder of Bicara Therapeutics Inc.?
Currently, no hedge funds are holding shares in BCAX
---
Bicara Therapeutics Inc. Stock Smart Score
Company Description
Bicara Therapeutics Inc.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
---
BCAX Stock 12 Month Forecast
Average Price Target
$40.00
▲(201.66% Upside)
Technical Analysis
Arbutus Biopharma
―
Anavex Life Sciences
―
Cogent Biosciences
―
Dianthus Therapeutics
―
LENZ Therapeutics
―
Best Analysts Covering BCAX
1 Year
1 Year Success Rate
1/5 ratings generated profit
1 Year Average Return
-29.58%
reiterated a buy rating 9 days ago
Copying Judah Frommer's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -29.58% per trade.
---